10 July 2020 - Takeda's Adcetris (brentuximab vedotin) has won the backing of the National Institute for Health and Care Excellence as a treatment for untreated systemic anaplastic large cell lymphoma, a rare type of lymphoma.

The decision allows NHS funding for the drug alongside cyclophosphamide, doxorubicin and prednisone (CHP), giving patients access to the first new front-line treatment option for the condition in several decades.

To date, frontline treatment for newly diagnosed sALCL patients has typically been multi-agent chemotherapy, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), which is generally associated with poor outcomes, with many patients failing to achieve long-term survival, the firm notes.

Read Pharma Times article